Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Merck KGaA (0O14) Company Description: Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment provides laboratory consumables and ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...

Modifi Bio’s founders discuss the journey from developing a cancer treatment drug to being acquired by Big Pharma.

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...